However, in 2017, the FDA approved a subretinal delivery of AAV2-mediated voretigene neparvovec-rzyl (Luxturna®, Spark Therapeutics, Inc., Philadephia, PA, USA) for the treatment of inherited biallelic RPE65 mutation-associated retinal dystrophy [8]. The gene discussed is RPE65; the disease is Retinal dystrophy.